Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

NCT05400070 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Sintilimab
Lung Cancer
Anlotinib
Chemotherapy

Interventions

DRUG: Neoadjuvant therapy 1

Sponsor

Tang-Du Hospital